Sectoral Asset Management Inc reduced its position in Celgene Corporation (NASDAQ:CELG) by 14.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 233,768 shares of the biopharmaceutical company’s stock after selling 38,298 shares during the quarter. Celgene comprises approximately 3.3% of Sectoral Asset Management Inc’s portfolio, making the stock its 10th biggest position. Sectoral Asset Management Inc’s holdings in Celgene were worth $30,359,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Neuberger Berman Group LLC boosted its holdings in shares of Celgene by 4.0% in the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after acquiring an additional 71,729 shares during the period. Grisanti Capital Management LLC acquired a new stake in shares of Celgene in the second quarter valued at approximately $3,616,000. Lincoln Capital Corp boosted its holdings in shares of Celgene by 0.6% in the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after acquiring an additional 185 shares during the period. RiverPoint Capital Management LLC boosted its holdings in shares of Celgene by 3.1% in the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock valued at $15,799,000 after acquiring an additional 3,680 shares during the period. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Celgene by 9.2% in the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after acquiring an additional 54,210 shares during the period. 80.17% of the stock is owned by institutional investors and hedge funds.
In other news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares in the company, valued at $564,768.25. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the transaction, the director now owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. Corporate insiders own 0.95% of the company’s stock.
Celgene Corporation (NASDAQ CELG) opened at $102.61 on Tuesday. The stock has a market capitalization of $80,790.00, a price-to-earnings ratio of 15.96, a price-to-earnings-growth ratio of 0.79 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Corporation has a 52-week low of $94.55 and a 52-week high of $147.17.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. Celgene’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.58 earnings per share. equities analysts expect that Celgene Corporation will post 6.67 EPS for the current fiscal year.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.